FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
ALOXI
palonosetron hydrochloride
LOE Approaching
Helsinn
ORAL · CAPSULE
2008
NDA30/100
ALOXI
palonosetron hydrochloride
LOE Approaching
Helsinn
INTRAVENOUS · INJECTABLE
acute nauseavomiting associated with initial+7
2003
NDA30/100
ALPHAGAN
brimonidine tartrate
LOE Approaching
AbbVie
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
1997
NDA30/100
ALPHAGAN
brimonidine tartrate
LOE Approaching
AbbVie
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
1996
NDA30/100
ALPHAGAN P
brimonidine tartrate
LOE Approaching
AbbVie
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
2001
NDA30/100
ALPHAGAN P
brimonidine tartrate
LOE Approaching
AbbVie
OPHTHALMIC · SOLUTION/DROPS
elevated intraocular pressure (IOP) in patients with open-angle glaucomaocular hypertension+2
2005
NDA30/100
ALPHATREX
betamethasone dipropionate
LOE Approaching
TOPICAL · OINTMENT
1984
NDA30/100
ALPHATREX
betamethasone dipropionate
LOE Approaching
TOPICAL · CREAM
1984
NDA30/100
ALREX
loteprednol etabonate
LOE Approaching
Bausch + Lomb
OPHTHALMIC · SUSPENSION/DROPS
1998
NDA30/100
ALTACE
ramipril
LOE Approaching
Pfizer
ORAL · TABLET
hypertensionto lower blood pressure+23
2007
SMNDA30/100
ALTACE
ramipril
LOE Approaching
Pfizer
ORAL · CAPSULE
hypertensionto lower blood pressure+23
1991
SMNDA30/100
ALTOPREV
lovastatin
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGYClinical Studies)+11
2002
SMNDA30/100
ALUPENT
metaproterenol sulfate
LOE Approaching
Boehringer Ingelheim
INHALATION · SOLUTION
1980
NDA30/100
ALUPENT
metaproterenol sulfate
LOE Approaching
Boehringer Ingelheim
INHALATION · AEROSOL, METERED
1973
NDA30/100
ALUPENT
metaproterenol sulfate
LOE Approaching
Boehringer Ingelheim
ORAL · SYRUP
1975
NDA30/100
ALUPENT
metaproterenol sulfate
LOE Approaching
Boehringer Ingelheim
ORAL · TABLET
1974
NDA30/100
ALUPENT
metaproterenol sulfate
LOE Approaching
Boehringer Ingelheim
INHALATION · SOLUTION
1983
NDA30/100
AMARYL
glimepiride
LOE Approaching
Sanofi
ORAL · TABLET
type 2 diabetes mellitus ( )type 1 diabetes mellitus+1
1995
NDA30/100
AMBENYL
bromodiphenhydramine hydrochloride; codeine phosphate
LOE Approaching
Forest Devices
ORAL · SYRUP
1954
NDA30/100
AMBIEN
zolpidem tartrate
LOE Approaching
ORAL · TABLET
insomnia
1992
NDA30/100
AMBIEN CR
zolpidem tartrate
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
insomnia
2005
NDA30/100
AMBISOME
amphotericin b
LOE Approaching
Astellas
INJECTION · INJECTABLE, LIPOSOMAL
Cryptococcal Meningitis in HIV-infected patients (see )unacceptable toxicity precludes the use of amphotericin B deoxycholate+1
1997
NDA30/100
AMERGE
naratriptan hydrochloride
LOE Approaching
GSK
ORAL · TABLET
1998
NDA30/100
AMERSCAN MDP KIT
technetium tc-99m medronate kit
LOE Approaching
INJECTION · INJECTABLE
1982
NDA30/100